Novartis and Zhejiang Tianyuan - Top 5 Emerging Markets Deals

Who: Novartis
Zhejiang Tianyuan
Where: China

Deal Size: $125 million

Details: In November 2009 Novartis forked over $125 million for 85 percent of Chinese vaccines maker Zhejiang Tianyuan. But that investment is just the tip of the iceberg. Novartis' then-CEO Daniel Vasella announced his intentions to make China the company's third largest market with a $1.25 billion investment in the country. (Vasella has since been replaced by Joe Jiminez).

Tianyuan is a privately-owned vaccine company with a range of marketed and experimental products focused on preventable viral and bacterial diseases. The vaccinemaker has seen its sales grow sharply since 2006 to $25 million in 2008. Novartis said it would invest in expanding Tianyuan's vaccine pipeline, manufacturing technologies and commercial networks.

Novartis and Zhejiang Tianyuan - Top 5 Emerging Markets Deals

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.